AI Summary
This article discusses a new finding about the interaction between 14-3-3θ and TDP-43 in TDP-43 proteinopathies, which are associated with ALS/FTD. The study shows that this interaction affects both loss-of-function and gain-of-toxic pathology related to TDP-43. The authors also suggest a potential gene therapy targeting 14-3-3θ to reduce deficits caused by TDP-43 in transgenic mice. This research could have implications for developing treatments for ALS and FTD.
In this issue of Neuron, Ke et al. report a novel non-canonical interaction between 14-3-3θ and TDP-43 that impacts loss-of-function and gain-of-toxic pathology in TDP-43 proteinopathies. The authors further provide proof of principle for a 14-3-3θ-targeted gene therapy to reduce TDP-43-induced deficits in transgenic TDP-43 mutant mice.